The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AXGN | +75.09% | +69.04% | +11.07% | +803% |
| S&P | +14.08% | +93.57% | +14.12% | +523% |
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm’s products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $60.08M | 23.5% |
| Gross Profit | $45.99M | 26.2% |
| Gross Margin | 76.55% | 1.6% |
| Market Cap | $820.86M | 33.6% |
| Market Cap / Employee | $1.82M | 0.0% |
| Employees | 452 | 5.6% |
| Net Income | $0.71M | 138.1% |
| EBITDA | $3.75M | 127.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $27.90M | 13.1% |
| Accounts Receivable | $30.78M | 25.0% |
| Inventory | 40.6 | 38.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $65.58M | -2.1% |
| Short Term Debt | $2.34M | 25.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -1.03% | 6.4% |
| Return On Invested Capital | -13.02% | 3.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $1.70M | -48.5% |
| Operating Free Cash Flow | $3.22M | -17.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 7.29 | 7.86 | 4.69 | 7.27 | 17.18% |
| Price to Sales | 4.23 | 4.30 | 2.56 | 4.08 | 19.90% |
| Price to Tangible Book Value | 7.70 | 8.31 | 4.96 | 7.69 | 17.42% |
| Price to Free Cash Flow TTM | 552.38 | 703.34 | 105.34 | 262.12 | - |
| Enterprise Value to EBITDA | 213.83 | 3966.74 | 158.32 | 240.90 | -39.22% |
| Free Cash Flow Yield | 0.2% | 0.1% | 0.9% | 0.4% | - |
| Return on Equity | -10.0% | -7.2% | -4.5% | -1.9% | -86.87% |
| Total Debt | $68.69M | $68.44M | $68.19M | $67.91M | -1.38% |
No podcast episodes available.
AXGN earnings call for the period ending September 30, 2021.
AXGN earnings call for the period ending June 30, 2021.
AXGN earnings call for the period ending March 31, 2021.
AXGN earnings call for the period ending September 30, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
